What is the recommended dose of misoprostol (prostaglandin E1 analog) for a 4-month pregnancy termination?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Misoprostol Dosing for 4-Month (Second Trimester) Pregnancy Termination

For second trimester pregnancy termination at 4 months (approximately 13-20 weeks), use vaginal misoprostol 400 mcg every 3 hours up to 5 doses, which is the most effective regimen when mifepristone is unavailable. 1

Optimal Dosing Protocol

Vaginal administration is significantly superior to oral administration for mid-trimester termination, with a mean induction-to-delivery interval of 17.5 hours (vaginal) versus 33 hours (oral), and 93% of women delivering within 24 hours with vaginal administration compared to only 19% with oral. 2, 3

Recommended Regimen (Misoprostol Alone):

  • Initial dose: 400 mcg vaginally
  • Subsequent doses: 400 mcg vaginally every 3 hours
  • Maximum: Up to 5 doses 1
  • Alternative protocol: 800 mcg initial vaginal dose, followed by 400 mcg orally every 3 hours (maximum 3 additional doses) 4

Enhanced Regimen (With Mifepristone - Preferred When Available):

  • Mifepristone: 200 mg orally first
  • Wait: 36-48 hours
  • Misoprostol: 800 mcg vaginally, then 400 mcg vaginally every 3 hours (maximum 4 additional doses) 5
  • This combination achieves 97.9% abortion rate within 24 hours and median induction-to-abortion interval of only 6.7 hours 5

Critical Safety Considerations

Absolute contraindication: Never use misoprostol in women with previous cesarean delivery due to 13% uterine rupture risk, substantially higher than oxytocin (1.1%) or prostaglandin E2 (2%). 6, 7

Monitoring Requirements:

  • Continuous fetal heart rate and uterine activity monitoring from 30 minutes to 2 hours after each administration 7, 8
  • Monitor for uterine hyperstimulation, which occurs less frequently with vaginal versus oral routes 7

Expected Outcomes and Management

Efficacy:

  • Vaginal misoprostol alone: 85-93% delivery within 24 hours 2, 3
  • With mifepristone pretreatment: 97.9% within 24 hours, 99.5% within 36 hours 5
  • Failure rate: Approximately 1-2% may require surgical intervention 4, 5

Common Side Effects:

  • Gastrointestinal symptoms (nausea/vomiting): 22% 4
  • Fever/chills: 20-25% 4, 3
  • Abdominal cramping (expected therapeutic effect) 1
  • Bleeding (expected) 1

Complications Requiring Intervention:

  • Incomplete abortion or retained placenta: 5-20% may require manual removal or curettage 4, 5
  • Infection: Rare but monitor for febrile morbidity 3
  • Uterine rupture: Extremely rare with appropriate dosing and no prior cesarean 1

Common Pitfalls to Avoid

  • Do not use oral route as first-line - vaginal administration is significantly more effective with shorter induction times 2, 3
  • Do not exceed recommended dosing frequency - higher doses increase side effects without improving efficacy 7, 1
  • Do not use in women with prior cesarean delivery - unacceptably high rupture risk 6, 7
  • Do not use beyond 30 weeks without dose reduction - reduce to 50-100 mcg vaginally every 3 hours due to increased uterine rupture risk 4

Cost and Practical Advantages

Misoprostol is significantly more cost-effective at $0.36-$1.20 per 100 mcg tablet compared to dinoprostone ($65-$165), and remains stable at room temperature without refrigeration requirements. 7

References

Research

Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2007

Guideline

Induction of Labour Methods and Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Oral Misoprostol Solution for Labor Induction

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Vaginal Misoprostol Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.